University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Lee-may Chen, MD

Lee-may Chen, MD

Clinical Professor, Department of Obstetrics, Gynecology, and Reproductive Sciences, UCSF
John A. Kerner Distingished Professor in Gynecologic Oncology

Cancer Center Program Memberships

Cancer Genetics

Research Summary

Dr. Lee-may Chen is the Division Director and Program Director for the UCSF/KPSF Gynecologic Oncology Fellowship Program. She is deeply committed to education and improving the outcomes of gynecologic cancer care.

Since 2008, I have been the director of the UCSF Gynecologic Cancer Risk Program. With a strong collaboration between the Cancer Genetics and Prevention Program and the Department of Pathology, we have long been interested in identifying at-risk individuals and families for hereditary cancer syndromes. The decision for risk-reducing surgery is fraught with unknowns and anxiety for patients. By studying patient centered outcomes, we are better able to counsel women and personalize their decision making.

We are also working closely with the Medical Center on their Perioperative Pathway Program. By creating a surgical pathway for open & minimally invasive surgery cases, we have been able to reduce hospital length of stay and decrease costs without compromising patient satisfaction. Surgical pathways also proves a robust platform to teach quality improvement, and we have integrated medical students, residents, and fellows into various performance improvement projects (opiate disposal, bowel prep) along the patients’ journey.


University of Michigan, Ann Arbor, MI, B.S., 1985-1989, Biomedical Sciences
University of Michigan Medical School, Ann Arbor, MI, M.D., 1988-1992, Chinese Studies, Medicine
University of Michigan Hospitals, Ann Arbor, MI, Residency, 1992-1996, Obstetrics & Gynecology
University of California, Los Angeles & Cedars-Sinai Medical Centers, Fellowship, 1996-1999, Gynecologic Oncology
University of California, San Francisco, San Francisco, CA, 2006-2007, Teaching Scholars Program
University of California, San Francisco, San Francisco, CA, 2010, Mentor Development Program

Professional Experience

  • 1999-2007
    Assistant Clinical Professor, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, & Reproductive Sciences, University of California, San Francisco
  • 2007-2011
    Associate Clinical Professor, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, & Reproductive Sciences, University of California, San Francisco
  • 2011-present
    Clinical Professor, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, & Reproductive Sciences, University of California, San Francisco

Honors & Awards

  • 1999
    ASCO/AACR Methods in Clinical Cancer Research Workshop
  • 2001
    Berlex Foundation, Junior Faculty Development Course
  • 2002
    ACOG/CREOG National Faculty Award
  • 2003-2005
    UCSF Department of Obstetrics, Gynecology, and Reproductive Sciences
  • 2007-2008
    Outstanding Resident Teaching Award
  • 2006
    Cancer Liason Physician Outstanding Performance Award
  • 2010
    Helen Diller Family Comprehensive Cancer Center Quality Award
  • 2010
    The Ernie H. Rosenbaum, MD Commitment to Patient Care Award
  • 2010-2015
    Edward C. Hill, MD, Endowed Chair

Selected Publications

  1. Manrriquez E, Chapman JS, Mak J, Blanco AM, Chen LM. Disparities in genetics assessment for women with ovarian cancer: Can we do better? Gynecol Oncol. 2018 Apr; 149(1):84-88.
    View on PubMed
  2. Liao CI, Chow S, Chen LM, Kapp DS, Mann A, Chan JK. Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US. Gynecol Oncol. 2018 Mar 04.
    View on PubMed
  3. Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, Ray-Coquard I, Bell-McGuinn K, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Konecny GE, Castro CM, Giordano H, Maloney L, Goble S, Lin KK, Sun J, Raponi M, Rolfe L, Kristeleit RS. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol. 2017 11; 147(2):267-275.
    View on PubMed
  4. Chapman CH, Maghsoudi K, Littell RD, Chen LM, Hsu IC. Salvage high-dose-rate brachytherapy and external beam radiotherapy for isolated vaginal recurrences of endometrial cancer with no prior adjuvant therapy. Brachytherapy. 2017 Nov - Dec; 16(6):1152-1158.
    View on PubMed
  5. Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. Oncotarget. 2017 Jul 18; 8(29):47154-47160.
    View on PubMed
  6. Ohliger MA, Hope TA, Chapman JS, Chen LM, Behr SC, Poder L. PET/MR Imaging in Gynecologic Oncology. Magn Reson Imaging Clin N Am. 2017 Aug; 25(3):667-684.
    View on PubMed
  7. Salani R, Khanna N, Frimer M, Bristow RE, Chen LM. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol. 2017 07; 146(1):3-10.
    View on PubMed
  8. Chen LM, Chen LL, Chapman JS. In Reply. Obstet Gynecol. 2017 01; 129(1):208.
    View on PubMed
  9. Westhoff GL, Fuh KC, Longacre TA, McNally JL, Hsu IC, Kapp DS, Teng N, Chen LM. Radiation Therapy for Recurrent Clear-Cell Cancer of the Ovary. Int J Gynecol Cancer. 2016 11; 26(9):1608-1614.
    View on PubMed
  10. Chen LM. STIC-ing with what we know. Gynecol Oncol. 2016 11; 143(2):227-228.
    View on PubMed
  11. Morgan RJ, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM, Copeland L, Crispens MA, DeRosa M, Dorigo O, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Percac-Lima S, Pineda M, Plaxe SC, Powell MA, Ratner E, Remmenga SW, Rose PG, Sabbatini P, Santoso JT, Werner TL, Burns J, Hughes M. Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 09; 14(9):1134-63.
    View on PubMed
  12. Chan JL, Letourneau J, Salem W, Cil AP, Chan SW, Chen LM, Rosen MP. Regret around fertility choices is decreased with pre-treatment counseling in gynecologic cancer patients. J Cancer Surviv. 2017 Feb; 11(1):58-63.
    View on PubMed
  13. S Chapman J, Roddy E, Panighetti A, Hwang S, Crawford B, Powell B, Chen LM. Comparing Coordinated Versus Sequential Salpingo-Oophorectomy for BRCA1 and BRCA2 Mutation Carriers With Breast Cancer. Clin Breast Cancer. 2016 Dec; 16(6):494-499.
    View on PubMed
  14. Chapman JS, Roddy E, Ueda S, Brooks R, Chen LL, Chen LM. Enhanced Recovery Pathways for Improving Outcomes After Minimally Invasive Gynecologic Oncology Surgery. Obstet Gynecol. 2016 07; 128(1):138-44.
    View on PubMed
  15. Kober KM, Dunn L, Mastick J, Cooper B, Langford D, Melisko M, Venook A, Chen LM, Wright F, Hammer M, Schmidt BL, Levine J, Miaskowski C, Aouizerat BE. Gene Expression Profiling of Evening Fatigue in Women Undergoing Chemotherapy for Breast Cancer. Biol Res Nurs. 2016 07; 18(4):370-85.
    View on PubMed
  16. Powell CB, Richardson DL, Chen LM. In response to Peshkin et al. "Genetic counseling and testing for hereditary cancer risk in young adult women: Facilitating autonomy and informed decision making is key". Gynecol Oncol Rep. 2015 Nov; 14:46.
    View on PubMed
  17. Brooks RA, Blansit K, Young-Lin N, Usach I, Chen LM, Yu X, Kapp DS, Chan JK. The economic impact of surgical care for morbidly obese endometrial cancer patients: a nationwide study. Am J Obstet Gynecol. 2016 Apr; 214(4):498.e1-498.e6.
    View on PubMed
  18. Chan JL, Letourneau J, Salem W, Cil AP, Chan SW, Chen LM, Rosen MP. Sexual satisfaction and quality of life in survivors of localized cervical and ovarian cancers following fertility-sparing surgery. Gynecol Oncol. 2015 Oct; 139(1):141-7.
    View on PubMed
  19. Tinkle CL, Weinberg V, Chen LM, Littell R, Cunha JAM, Sethi RA, Chan JK, Hsu IC. Inverse Planned High-Dose-Rate Brachytherapy for Locoregionally Advanced Cervical Cancer: 4-Year Outcomes. Int J Radiat Oncol Biol Phys. 2015 Aug 01; 92(5):1093-1100.
    View on PubMed
  20. Makker V, Filiaci VL, Chen LM, Darus CJ, Kendrick JE, Sutton G, Moxley K, Aghajanian C. Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N. Gynecol Oncol. 2015 Jul; 138(1):24-9.
    View on PubMed

Go to UCSF Profiles, powered by CTSI